At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ZLAB Zai Lab Ltd
Market Closed 01-31 16:00:00 EST
27.19
-0.65
-2.33%
盘后27.20
+0.01+0.04%
19:18 EST
High28.01
Low27.15
Vol773.59K
Open27.88
D1 Closing27.84
Amplitude3.09%
Mkt Cap2.96B
Tradable Cap2.71B
Total Shares108.94M
T/O21.25M
T/O Rate0.78%
Tradable Shares99.54M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Press Release: Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.